Compressed homologous cancellous bone and bone morphogenetic protein (BMP)-7 or bone marrow accelerate healing of long-bone critical defects

Djapic, T.; Kušec, Vesna; Jelić, Mislav; Vukičević, Slobodan; Pećina, Marko

doi:10.1007/s00264-003-0496-z

Cited by 17 publications

(9 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These materials are available in unlimited quantities in the hope of eliminating or limiting the need for harvesting iliac crest bone grafts. In the past 10 years, osteo-inductive materials, such as bone morphogenetic proteins, have received much attention, mostly as a result of their capacity to improve proliferation of osteotransforming cells derived from undifferentiated cells [7,13,14]. The rhBMPs have demonstrated healing rates in tibial non-unions similar to those in autogenous bone grafts from the iliac crest [8].…”

Section: Discussionmentioning

confidence: 99%

P-15 small peptide bone graft substitute in the treatment of non-unions and delayed union. A pilot clinical trial

Gomar

Orozco

Villar³

et al. 2006

International Orthopaedics (SICO

View full text Add to dashboard Cite

Treatment of non-unions and delayed unions often requires osteogenic material. Recently, a biomimetic bone matrix that simulates the cellular environment of hard tissue, identified as P-15, was introduced to the orthopaedic community. A total of 22 patients with mal-union or delayed union fractures was treated from June 2000 to October 2003 with P15- bone graft substitute (P15-BGS) in the site of fracture and mostly with internal fixation. Patients were examined by independent radiographic analysis. Assessment criteria included time elapsed until bone bridging and time to full consolidation. In addition, histological assessment of the callus was done at the time of recovery of metal implants in five patients. Full consolidation was achieved in 90% (20 out of 22) of the patients treated with P15-BGS. The average time for full consolidation was 4.2 months. Histological assessment of the fracture callus in five of the patients confirmed the positive clinical and radiographic results. P15-BGS appears to offer a safe, economical and clinically useful alternative to autograft in the repair of ununited fractures. These results compare favourably with those in the published literature as an alternative to autograft.

show abstract

Section: Discussionmentioning

confidence: 99%

P-15 small peptide bone graft substitute in the treatment of non-unions and delayed union. A pilot clinical trial

Gomar

Orozco

Villar³

et al. 2006

International Orthopaedics (SICO

View full text Add to dashboard Cite

show abstract

“…Bone marrow stromal cells (BMSCs) were named "mesenchymal stem cells" (MSCs) in the 1990s [1,8] and this term MSC will be used in the text. Due to the BMSC capacity for ex vivo expansion, BMSCs frequently are used in innovative therapeutic approaches [3] such as tissue engineering. The therapeutic potential of these cells has drawn considerable interest in the treatment of various orthopaedic conditions, ranging from spinal fusions, treatment of nonunions following traumatic injury, avascular necrosis as well as in challenging soft tissue sports medicine applications.…”

Section: Introductionmentioning

confidence: 99%

Benefits of small volume and small syringe for bone marrow aspirations of mesenchymal stem cells

Hernigou

Homma

Flouzat-Lachaniette

et al. 2013

International Orthopaedics (SICOT)

204

127

View full text Add to dashboard Cite

show abstract

“…Recombinant human BMP-2 was reported to accelerate normal fracture healing and healing of an allograft osteotomy in animal models [3,19,22,26], and rhBMP-2 has also been shown to be a safe and efficacious replacement for autogenous bone graft in lumbar interbody fusion [14,23]. Djapic et al [9] found that BMP-7 has a potential to stimulate osteogenesis in a comparable fashion to autologous bone marrow when it was used with compressed homologous cancellous bone for treating long-bone critical defects in an animal study. Clinically, rhBMP-2 has also been shown, when applied to open tibia fractures, to reduce the frequency of secondary interventions, accelerate fracture and wound healing, and reduce the infection rate [11].…”

Section: Discussionmentioning

confidence: 99%

Effects of rhBMP-2 on cortical strut allograft healing to the femur in revision total hip arthroplasties: an experimental study

Xiong

2006

International Orthopaedics (SICO

View full text Add to dashboard Cite

We have studied the effects of recombinant human bone morphogenetic protein-2 (rhBMP-2) on cortical strut allograft healing and remodelling in revision hip arthroplasty. Thirty adult New Zealand rabbits underwent bilateral onlay allograft strut procedures to the femur using wires. The left femur (experimental side) received the rhBMP-2 device (1.0-mg rhBMP-2/gelatin composites) interposed between the allograft and host bone, while the right side was grafted with an allograft strut as the control. The femurs and implants were retrieved at 4, 6, and 8 weeks postoperatively. The healing of cortical strut grafts to the femur was enhanced dramatically by the addition of the rhBMP-2 device in radiographic examination, contact radiographic examination, non-decalcification sections, fluorescence tag, and computer-aided image analysis. The remodelling of cortical strut allograft was also accelerated. The new bone formation ratio and radiographic scores of the experimental side were also much higher than the control side at all times. Strut healing with the rhBMP-2 device at 4 weeks postoperatively was superior to the healing in control sides at 8 weeks. Our findings showed that the rhBMP-2 device improved and accelerated the course of cortical strut allograft healing and remodelling with host bone.Résumé Nous avons étudié les effets de la BMP recombinante rhBMP-2 sur des allogreffes corticales dans les révisions de prothèses totales. 30 lapins adultes de Nouvelle Zélande ont bénéficié d'une allogreffe bilatérale sur un fémur cerclé avec interposition entre l'allogreffe et l'os receveur au niveau du fémur gauche de rhBMP-2 (1.0 mg rhBMP-2 de gélatines composites), le fémur droit étant greffé avec une allogreffe simple (groupe contrôle). Les fémurs et les implants ont été prélevés à 4, 6, 8 semaines post opératoires. La consolidation par allogreffe corticale a été considérablement améliorée par l'addition de rhBMP-2, tant sur le plan radiographique que sur le plan histologique. La consolidation avec rhBMP-2 à 4 semaines post opératoires est supérieure au groupe contrôle à 8 semaines. Notre expérimentation nous permet de montrer que le rhBMP-2 améliore la consolidation et le remodelage au niveau de l'os receveur des allogreffes corticales.

show abstract

Compressed homologous cancellous bone and bone morphogenetic protein (BMP)-7 or bone marrow accelerate healing of long-bone critical defects

Cited by 17 publications

References 19 publications

P-15 small peptide bone graft substitute in the treatment of non-unions and delayed union. A pilot clinical trial

P-15 small peptide bone graft substitute in the treatment of non-unions and delayed union. A pilot clinical trial

Benefits of small volume and small syringe for bone marrow aspirations of mesenchymal stem cells

Effects of rhBMP-2 on cortical strut allograft healing to the femur in revision total hip arthroplasties: an experimental study

Contact Info

Product

Resources

About